PDCD1 and neoplasm: In future trials, the use of repeated biopsies or multiple tumour sampling from head and neck tumours as well as reporting the actual value of PD-L1 expression could be considered for better prediction of tumour response to immune checkpoint inhibitors targeting the PD-1/PD-L1 signalling pathway.